Background: Clinical and molecular factors are essential to define
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Introduction
Primary GBMs occur more frequently in male patients with a mean age of diagnosis of 62 years; secondary GBMs have a predilection for female patients with a mean age of 45 years. Glioblastoma prognosis is poor with a median survival of 12-18 months and less than 10% of patients are alive 5 years after diagnosis. Patients surviving over 2 years after diagnosis have a higher survival probability compared to newly diagnosed patients [1, 2] .
Extent of surgical resection, performance status and age (> 50 years) are the most important and widely accepted clinical prognostic factors [3] [4] [5] [6] .
Other factors could impact on prognosis: site of tumors [1] ; body surface area (BSA) that is the only factor influencing temozolomide clearance and pharmacokinetics [7] ; marital status [8] and care center expertise. About this last topic, in the prospective study of the Project of Emilia-Romagna on Neuro-Oncology (PERNO), overall survival was related to treatment received in a high versus low-volume center [9] .
Various prognostic molecular markers have been identified in GBM, including methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter, isocitrate dehydrogenase enzyme 1/2 (IDH1/2) mutation, epidermal growth factor receptor (EGFR) overexpression and amplification, glioma-CpGisland methylator phenotype (G-CIMP), tumor protein (TP53) mutation and genetic losses of chromosomes [1] .
The role of gender has been investigated as potential prognostic factor.
Male patients have a significant survival advantage than female in the first year after the diagnosis, thereafter the difference is not significant [10] .The M A N U S C R I P T
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4 results of survival analysis of GBM patients included in the PERNO registry suggest a survival advantage for MGMT methylated females.
Methods
The Project of Emilia-Romagna Region on Neuro-Oncology (PERNO) was age ≥ 18 years; 3) KPS 30-100%, 4) no prior surgery for brain tumor; 5) residence within the Emilia-Romagna region [9, 11] .
Approval for the project was obtained from the Ethical Committee of each participating center and, before registration, informed written consent of the patient was obtained according to ICH/GCP and national recommendations.
MGMT methylation status was assessed through methylation-specific polymerase chain reaction (MSP). progression or unacceptable toxicities [9, 11] . 
Treatment
Statistical analysis
Results
One hundred sixty-nine GBM patients were treated with TMZ concomitant with and adjuvant to radiotherapy. Median age was 60 years (range 29 -82 years). Ninety-nine patients were male (58.6%) and 70 were female (41.4%).
According to MGMT methylation status assessment, 68 patients were MGMT M A N U S C R I P T A C C E P T E D Table 1 .
Survival
Survival was similar between male patients (15.6 months 95% CI 12.9 -18.4) and female patients (16.7 months 95% CI 13.5 -19.9) (P= 0.519).
Overall survival (OS) in MGMT methylated patients was 20.0 months (95% CI 14.2 -25.9) versus 14.1 months (95% CI 11.0 -17.2) in unmethylated patients (P= 0.001).
Combining gender and methylation status, at univariate analysis, we observed a significant survival improvement for methylated females compared to methylated males: the female methylated group did not reach the median survival, however overall survival at 12 months (OS12) was significantly higher with respect to male methylated group (78.1% vs 66.7% P= 0.028). No significant difference was found between unmethylated females and unmethylated males (P=0.158) [ Figure 1 ].
Multivariate analysis [ Table 2 ] showed that gender and MGMT methylation status simultaneously considered (P< 0.000), age (P= 0.032) and performance status (P= 0.000) were the most important prognostic factors. Radical resection rate was not significantly different between female methylated group and other groups (62.5% vs 51.4%, P= 0,574).
Age, performance status and extent of surgical resection are well known prognostic factors for GBM.
In a randomized EORTC-NCIC phase III trial [13] 
It was hypothesized that pharmacodynamic, pharmacokinetic and molecular factors can create some differences among male and female patients, but a clear explanation of this is still unknown.
Females have a different body fat distribution, which may influence the absorption of the drug and a lower glomerular filtration rate with a consequent decreased elimination.
Some evidences [16, 17] showed that sexual dimorphism might modulate the biology of GBM. In mice models, male exhibited higher proliferation and enhanced tumorigenesis compared to female counterparts [16] . Further, the tumors showed a more extensive necrosis in male patients than in female, due to the association of tumor cell death with MYC increased activity in female and with TP53 activity in male patients [17] .
In 2016, a report by Schiffgens et al. analyzed sex-specific differences in relation to survival in GBM patients through the evaluation of a novel biomarker that promotes tumor progression: the Wnt receptor Frizzled-7 (FZD7). In this study, methylated MGMT promoter was found to be significantly associated with longer survival in female patients.
Interestingly, combining FZD7 and MGMT methylation, sex-specific differences were deleted [18] . In addition, the role of gender has to be reminded when considering toxicity. The incidence of grade 3-4 hematological toxicity in GBM patients treated with temozolomide is in the range of 7% [12] .
In a trial of 445 patients treated with TMZ, a higher incidence (11%) of significant myelotoxicity was reported in female patients. Older female
patients who received higher doses had a major chance to develop both neutropenia and thrombocytopenia [7] . 
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MGMT methylation status confirms its role of important prognostic factor (median survival 20.0 months for methylated group vs 14.1 months for unmethylated group, P= 0.001).
When considering MGMT methylation status with gender, we observed a survival benefit in methylated female patients (met vs unmet p< 0.001) but, interestingly, not in male patients (met vs unmet P= 0.395).
At multivariate analysis, simultaneous evaluation of patients' gender and MGMT methylation status has a significant prognostic role: MGMT methylation is associated with longer survival in female patients when 
Conclusion
The results of this PERNO registry analysis is of particular interest to drive oncologists in their clinical choices to select GBM patients to treat with standard treatment. MGMT methylated promoter has already been shown to be associated with a better prognosis but also gender should be considered as a potential prognostic factor and a predictive factor for myelotoxicity.
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Highlights
• MGMT methylation is a relevant prognostic factor for glioblastoma patients.
• From literature a prognostic advantage for female patients has been reported.
• In this analysis we report a survival benefit for methylated female GBM patients. 
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